Skip to content

Advertisement

  • Poster presentation
  • Open Access

Risk factors for advanced liver fibrosis in HIV-infected individuals: role of the metabolic syndrome

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Journal of the International AIDS Society200811 (Suppl 1) :P137

https://doi.org/10.1186/1758-2652-11-S1-P137

  • Published:

Keywords

  • Alcohol Abuse
  • Tenofovir
  • Atazanavir
  • HOMA Index
  • Advance Liver Fibrosis

Background

Liver damage in HIV patients may result from multiple factors. The availability of reliable non-invasive tools to measure liver fibrosis, such as transient elastometry (FibroScan), has permitted the screening of large populations.

Methods

Cross-sectional study of all HIV outpatients who underwent examination by FibroScan at one HIV reference clinic since 2005. Advanced liver fibrosis (ALF) was defined as hepatic stiffness >9.5 kiloPascals, which corresponds to Metavir stages F3–F4 in the liver biopsy. Main demographics, alcohol abuse, antiretroviral exposure, biochemistry, HOMA index, immune and viral parameters, and hepatitis B or C status were evaluated.

Summary of results

A total of 681 consecutive HIV patients (64% injecting drug users; mean age 43 years; 78% male; 77% on antiretroviral therapy) had a valid FibroScan evaluation. Main characteristics: mean CD4 count 524 (309) cells/mm3, plasma HIV-RNA <50 cp/mL 72%, HBsAg+ 8.5%, HCV-RNA+ 60%, mean BMI 23.6 (3.9) kg/m2, past and current alcohol abuse (>60 g/d) 33% and 10%, respectively. ALF was diagnosed in 215 (32%).

In the univariate analysis, significant differences were found between patients with and without ALF for mean age (44 vs. 42 years), risk behaviour (IDU 81 vs. 54%, MSM 11 vs. 33%, heterosex 6 vs. 12%), past alcohol abuse (50 vs. 26%), mean CD4+ count (469 vs. 550 cells/mm3), HCV-RNA+ (77 vs 52%), ALT >50 IU/L (29 vs 9%), mean plasma glucose (127 vs. 116 mg/dL), triglycerides (223 vs. 172 mg/dL), and total cholesterol (177 vs. 188 mg/dL), HOMA index (4.5 vs. 3.2), past exposure to ddI +/- d4T (51 vs. 40%), and mean months on NVP (11 vs. 16), LPV (13 vs. 8), atazanavir (7 vs. 5), tenofovir (21 vs. 18) as well as any antiretroviral (85 vs. 78).

In a multivariate model (OR, 95% CI), older age (1.08, 1.04–1.13), past alcohol abuse (2.62, 1.60–4.28), exposure to ddI and/or d4T (1.94, 1.20–3.16), higher HOMA index (1.25, 1.04–1.51) and elevated ALT (1.05, 1.03–1.06) were all independently associated with ALF; in contrast, chronic hepatitis B or C were no longer associated with ALF.

Conclusion

Former alcohol abuse and non-alcoholic steatohepatitis as a result of insulin resistance and/or exposure to dideoxy-nucleosides represent an emerging cause of ALF in HIV patients.

Authors’ Affiliations

(1)
Hospital Carlos III, Madrid, Spain

References

  1. Vergara S, et al: The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2007, 45: 969-974. 10.1086/521857.PubMedView ArticleGoogle Scholar
  2. Soriano V, et al: Antiretroviral drugs and liver injury. AIDS. 2008, 22: 1-13. 10.1097/QAD.0b013e3282f82b96.PubMedView ArticleGoogle Scholar

Copyright

© Blanco et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement